-
Mashup Score: 20
In the Phase 2b/3 trial, clesrovimab reduced RSV-associated hospitalizations (secondary endpoint) and RSV-associated lower respiratory infection hospitalizations (tertiary endpoint) by more than 84% and 90%, respectively, through 5 months Clesrovimab has the potential to become the first and only approved immunization designed to protect infants with the same single dose regardless of weight for the duration of their first RSV season RAHWAY, N.J., Oct. 17, 2024 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of positive results from the Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, the company’s investigational prophylactic monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) disease during their first RSV season. The results, along with interim findings from the ongoing Phase 3 trial (MK-1654-007) of clesrovimab, were presented during IDWeek 2024, held October 16-19 in Los
Source: www.merck.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 20
In the Phase 2b/3 trial, clesrovimab reduced RSV-associated hospitalizations (secondary endpoint) and RSV-associated lower respiratory infection hospitalizations (tertiary endpoint) by more than 84% and 90%, respectively, through 5 months Clesrovimab has the potential to become the first and only approved immunization designed to protect infants with the same single dose regardless of weight for the duration of their first RSV season RAHWAY, N.J., Oct. 17, 2024 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of positive results from the Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, the company’s investigational prophylactic monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) disease during their first RSV season. The results, along with interim findings from the ongoing Phase 3 trial (MK-1654-007) of clesrovimab, were presented during IDWeek 2024, held October 16-19 in Los
Source: www.merck.comCategories: General Medicine News, PayerTweet-
Today, we shared positive results from our late-stage clinical program in respiratory syncytial virus (#RSV) disease. Learn more here: https://t.co/3xTOtvbdRZ https://t.co/JBdccutfXR
-
-
Mashup Score: 9
University of Minnesota http://twin-cities.umn.edu/ 612-625-5000 Just 26% of US adults say they are concerned that they or a family member may be infected by respiratory syncytial virus (RSV) in the next 3 months, down from 35% last year, while the proportion worried about COVID-19 and flu stayed the same, according to the latest health survey from the Annenberg Public Policy Center (APPC) at the University of Pennsylvania. Each year, 100,000 older US adults and 58,000 infants and children younger than 5
Source: www.cidrap.umn.eduCategories: General Medicine News, Infectious DiseaseTweet-
Survey: Only a quarter of US adults concerned about #RSV, down from 35% in 2023 Less than half recognized some of the most common infant RSV symptoms. https://t.co/En9VAq1J6U https://t.co/ZfRDiBr4Qq
-
-
Mashup Score: 9
University of Minnesota http://twin-cities.umn.edu/ 612-625-5000 Just 26% of US adults say they are concerned that they or a family member may be infected by respiratory syncytial virus (RSV) in the next 3 months, down from 35% last year, while the proportion worried about COVID-19 and flu stayed the same, according to the latest health survey from the Annenberg Public Policy Center (APPC) at the University of Pennsylvania. Each year, 100,000 older US adults and 58,000 infants and children younger than 5
Source: www.cidrap.umn.eduCategories: General Medicine News, Infectious DiseaseTweet-
Survey: Only a quarter of US adults concerned about #RSV, down from 35% in 2023 Less than half recognized some of the most common infant RSV symptoms. https://t.co/En9VAq1J6U https://t.co/ZfRDiBr4Qq
-
-
Mashup Score: 28Nirsevimab 76% effective against severe RSV in infants in 2023-24 season, researchers estimate - 1 month(s) ago
The estimated effectiveness of the vaccine was higher (80%) in babies in a catch-up group.
Source: www.cidrap.umn.eduCategories: General Medicine News, Infectious DiseaseTweet-
Nirsevimab 76% effective against severe #RSV in infants in 2023-24 season, researchers estimate The estimated effectiveness of the vaccine was higher (80%) in babies in a catch-up group. https://t.co/BDPmsx9FLt https://t.co/pAwQ7zUXu4
-
-
Mashup Score: 28Nirsevimab 76% effective against severe RSV in infants in 2023-24 season, researchers estimate - 1 month(s) ago
The estimated effectiveness of the vaccine was higher (80%) in babies in a catch-up group.
Source: www.cidrap.umn.eduCategories: General Medicine News, Infectious DiseaseTweet-
Nirsevimab 76% effective against severe #RSV in infants in 2023-24 season, researchers estimate The estimated effectiveness of the vaccine was higher (80%) in babies in a catch-up group. https://t.co/BDPmsx9FLt https://t.co/pAwQ7zUXu4
-
-
Mashup Score: 0The Fight Against RSV Begins with Vaccination - 2 month(s) ago
The CDC recommends vaccination for pregnant individuals and the administration of the RSV antibody nirsevimab to infants under eight months.
Source: www.contagionlive.comCategories: General Medicine News, Infectious DiseaseTweet-
A recent study showed that only 32.6% of pregnant women received the RSV vaccine, and 44.6% of infants received nirsevimab, indicating a need for more provider recommendations. #RSV https://t.co/LoSaKfQHuO https://t.co/FweHxstsZ6
-
-
Mashup Score: 0
The addition of paired serology testing, standard care swab results, and independent testing of nasopharyngeal/oropharyngeal specimens improved RSV diagnostic yield.
Source: www.pulmonologyadvisor.comCategories: General Medicine News, PulmonologyTweet-
Addition of paired serology testing, standard care swab results, and separate testing of nasopharyngeal and oropharyngeal swabs improves the diagnostic yield for #RSV among hospitalized adults. Read More: https://t.co/gx2tqbaDcP
-
-
Mashup Score: 0High Burden of RSV in Infants - 2 month(s) ago
Over half of US infants are infected with respiratory syncytial virus (RSV) during infancy, with 2.8% requiring hospitalization.
Source: www.contagionlive.comCategories: General Medicine News, Infectious DiseaseTweet-
Recent study found that over 53% of US infants are infected with respiratory syncytial virus #RSV during infancy, with 2.8% requiring hospitalization. https://t.co/UFvAun0j1V https://t.co/h4vNy2Spag
-
-
Mashup Score: 0Improving Insurance Coverage for RSV Vaccines - 2 month(s) ago
The panel discusses what’s needed for payers to activate early coverage for RSV vaccines in adults and how coverage has been since the approval of the 2 RSV vaccines.
Source: www.ajmc.comCategories: General Medicine News, General HCPsTweet-
Experts discuss what’s needed for payers to activate early coverage for respiratory syncytial virus (RSV) vaccines in adults and examine how coverage has been since the approval of the 2 RSV vaccines. Watch the episode here: https://t.co/SQU25eUTaM #RSV
-
Today, we shared positive results from our late-stage clinical program in respiratory syncytial virus (#RSV) disease. Learn more here: https://t.co/3xTOtvbdRZ https://t.co/JBdccutfXR